RADX

Radiopharm Theranostics Stock Analysis

AI Rating

Low
  • Quality1/10
  • Growth↓ 0/10
  • Momentum↑ 5/10
Radiopharm Theranostics sales and earnings growth
RADX Growth
Low
  • Revenue Y/Y↑ 1142.79%
  • EPS Y/Y↑ 84.45%
  • FCF Y/Y↓ -57.63%
Radiopharm Theranostics gross and profit margin trends
RADX Profitability
Neutral
  • Gross margin ↓ 1.10%
  • EPS margin↓ -997.40%
  • ROIC↓ -149.70%
Radiopharm Theranostics net debt vs free cash flow
RADX Risk
Great
  • Debt / Equity↓ 0.7
  • Debt / FCF↓ 0.1
  • Interest coverage↓ -552.4

Radiopharm Theranostics stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗